Safety and efficacy of iopromide in cerebral arteriography.
Invest Radiol
; 29 Suppl 1: S94-7, 1994 May.
Article
en En
| MEDLINE
| ID: mdl-8071052
ABSTRACT
RATIONALE AND OBJECTIVES:
Iopromide is a new nonionic monomeric contrast medium for cerebral arteriography. This agent has been approved for sale in over 45 countries; however, it is still undergoing clinical review in the United States. This study evaluated the safety and efficacy of iopromide in comparison with two other nonionic contrast media.METHODS:
A total of 173 patients participated in the study, which was prospective, double-blind, and randomized. In two centers, patients received iopromide or iohexol; in the other three centers, patients received iopromide or iopamidol. Adverse events were monitored by investigators, and efficacy was evaluated by grading the radiographic images.RESULTS:
Most adverse events were mild or moderate in severity; all resolved completely. Twenty-one percent of patients given iopromide were reported to have a drug-related adverse event, versus 44% of patients given a comparator. No statistically significant difference emerged between iopromide and the comparators with regard to efficacy.CONCLUSIONS:
These study results indicate that iopromide is a safe and effective contrast medium for cerebral angiography.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Yohexol
/
Angiografía Cerebral
/
Medios de Contraste
Tipo de estudio:
Clinical_trials
/
Observational_studies
Límite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Invest Radiol
Año:
1994
Tipo del documento:
Article